Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:GMTX NASDAQ:IMVT NASDAQ:KALV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$20.59+1.0%$21.06$19.00▼$26.58$2.52B0.71.31 million shs814,373 shsGMTXGemini Therapeutics$59.95+0.3%$57.41$1.16▼$14.10$2.60B-0.12189,291 shs165,212 shsIMVTImmunovant$14.69-0.9%$16.33$12.72▼$34.47$2.56B0.661.45 million shs805,646 shsKALVKalVista Pharmaceuticals$13.46-0.4%$13.47$7.30▼$16.32$677.58M0.05775,820 shs436,472 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.94%-0.88%-3.00%-18.12%0.00%GMTXGemini Therapeutics+0.28%+2.09%+0.79%+27.91%+21.16%IMVTImmunovant-2.37%-0.13%-10.99%-0.34%-52.73%KALVKalVista Pharmaceuticals-0.59%+4.24%-1.75%+14.88%+4.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.8646 of 5 stars3.61.00.03.92.73.33.8GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant2.9836 of 5 stars4.42.00.00.03.01.70.0KALVKalVista Pharmaceuticals3.7035 of 5 stars3.61.00.04.42.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$33.2061.24% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AIMVTImmunovant 2.83Moderate Buy$35.20139.62% UpsideKALVKalVista Pharmaceuticals 3.11Buy$26.2995.29% UpsideCurrent Analyst Ratings BreakdownLatest KALV, IMVT, GMTX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$17.00 ➝ $18.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.007/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $27.007/7/2025KALVKalVista PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.12$2.50 per share8.25$6.99 per share2.95GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AIMVTImmunovantN/AN/AN/AN/A$3.49 per shareN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.6512.489.670.8237.36%40.78%35.36%11/5/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)KALVKalVista Pharmaceuticals-$183.44M-$3.69N/AN/AN/AN/A-134.07%-82.65%9/4/2025 (Estimated)Latest KALV, IMVT, GMTX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91N/AN/AN/A$1.97 millionN/A8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.716.55GMTXGemini TherapeuticsN/A71.4971.49IMVTImmunovantN/A12.3212.32KALVKalVista PharmaceuticalsN/A5.355.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%GMTXGemini Therapeutics75.42%IMVTImmunovant47.08%KALVKalVista PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%GMTXGemini Therapeutics12.90%IMVTImmunovant1.80%KALVKalVista Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableKALVKalVista Pharmaceuticals10050.34 million48.18 millionOptionableKALV, IMVT, GMTX, and CPRX HeadlinesRecent News About These CompaniesNicole Sweeny Sells 1,864 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) StockAugust 28 at 8:17 AM | marketbeat.comKalVista Pharmaceuticals Stock Sees RS Rating Rise To 82August 28 at 2:51 AM | msn.comInsider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 2,942 Shares of StockAugust 27 at 8:58 PM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,940 SharesAugust 27 at 8:35 PM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,480 SharesAugust 27 at 7:37 AM | insidertrades.comKalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025August 27 at 7:11 AM | mms.businesswire.comStonepine Capital Management LLC Acquires New Holdings in KalVista Pharmaceuticals, Inc. $KALVAugust 26 at 7:38 AM | marketbeat.comPaul Audhya Sells 2,942 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) StockAugust 26 at 5:07 AM | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by BrokeragesAugust 19, 2025 | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 3.7% - Time to Buy?August 16, 2025 | marketbeat.comStocks To Watch: KalVista Pharmaceuticals Sees Relative Strength Rating Rise To 82August 15, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50-Day Moving Average - Time to Sell?August 14, 2025 | marketbeat.comStocks With Rising Relative Strength: KalVista PharmaceuticalsAugust 12, 2025 | msn.comMetagenomi Appoints Laurence Reid, PhD to its Board of DirectorsAugust 11, 2025 | globenewswire.comKalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European UnionAugust 11, 2025 | finance.yahoo.comKaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria’s navenibart in JapanAugust 7, 2025 | fiercebiotech.comFKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 | businesswire.comEMA Backs First Oral Treatment for Hereditary AngioedemaJuly 29, 2025 | medscape.comMKalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines AgencyJuly 29, 2025 | msn.comKalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)July 27, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, IMVT, GMTX, and CPRX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$20.59 +0.21 (+1.03%) Closing price 04:00 PM EasternExtended Trading$20.42 -0.16 (-0.80%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Gemini Therapeutics NASDAQ:GMTX$59.95 +0.17 (+0.28%) As of 08/27/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Immunovant NASDAQ:IMVT$14.69 -0.13 (-0.88%) Closing price 04:00 PM EasternExtended Trading$14.51 -0.18 (-1.22%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.KalVista Pharmaceuticals NASDAQ:KALV$13.46 -0.05 (-0.37%) Closing price 04:00 PM EasternExtended Trading$13.75 +0.29 (+2.15%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access